생화학분자생물학회

	Tae Kon Kim ( tae.k.kim@vumc.org, kim.taekon@gmail.com )
	12/21-present	Staff physician, Bone Marrow Transplant, Veterans Affairs Medical Center, Tennessee Valley Healthcare System, Nashville, TN
	07/19-present	Assistant Professor, Division of Hematology/Oncology, Dept of Medicine, Dept of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN
	07/19-present	Adjunt Assistant Professor, Section of Medical Oncology, Yale School of Medicine, New Haven, CT
	07/16-06/19	Clinical Instructor, Section of Hematology, Yale School of Medicine, New Haven, CT
	07/13-06/16	Fellow, Program in Hematology/Oncology, Yale-New Haven Hospital, New Haven, CT
	06/10-06/13	Resident, Internal Medicine, Univ. of Miami/Jackson Memorial Hospital, Miami, FL
	08/05-06/10	Graduate Research Associate, Univ. of Texas, MD Anderson Cancer Center, TX
	11/02-07/05	Visiting scholar in Hematology, University of Pennsylvania, Philadelphia, PA
	03/01-02/02	Intern, Internal Medicine, Seoul National University Hospital, Seoul, S. Korea

VISTA-mediated immune evasion in cancer

Over the past decade, V-domain immunoglobulin suppressor of T-cell activation (VISTA) has been established as a negative immune checkpoint molecule. Since the role of VISTA in inhibiting T-cell activation was described, studies have demonstrated other diverse regulatory functions in multiple immune cell populations. Furthermore, its relevance has been identified in human cancers. The role of VISTA in cancer immune evasion has been determined, but its mechanisms in the tumor microenvironment remain to be further elucidated. Understanding its contributions to cancer initiation, progression, and resistance to current treatments will be critical to its utility as a target for novel immunotherapies. Here, we summarize the current understanding of VISTA biology in cancer.

Exp Mol Med. 2024 Nov;56(11):2348-2356. doi: 10.1038/s12276-024-01336-6
https://pubmed.ncbi.nlm.nih.gov/39482534/